MONEY

Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)

Tomas Kauer - ModeratorTomas Kauer - Moderator
Oct 1, 2024 - 04:00
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (ustekinumab-aauz)
Read More

Tags:

Previous Article

Retractable Technologies, Inc. Declares Dividends to Series II and III Class B P...

Next Article

The PG&E Corporation Foundation and California Fire Foundation Announce Wildfire...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Earnings call: Curis reports on emavusertib progress in Q1 2024

Earnings call: Curis reports on emavusertib progress in...

Tomas Kauer - Mode... May 9, 2024

China cannot represent Taiwan and should work with Taipei on global challenges, Lai says

China cannot represent Taiwan and should work with Taip...

Tomas Kauer - Mode... Oct 10, 2024

Analysis-Extreme weather adds to fiscal strains in central Europe

Analysis-Extreme weather adds to fiscal strains in cent...

Tomas Kauer - Mode... Sep 20, 2024